The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Government Impact of Hep C Drug Price Tag

Back to News Homepage

Next

FREE WEBINAR Diagnosing and Treating HE: A Physician's Perspective

Gilead Gets Approved for Accelerated Assessment of Hep C Drug

Print this page

The European Medicines Agency will conduct a full assessment of Gilead Science’s Hepatitis C therapy.

Gilead Sciences receives EU green light for hepatitis C drug assessment

April 1, 2014 in Pharmaceutical Company Product News

Gilead Sciences has announced that the European Medicines Agency (EMA) has ratified its application for the assessment of a new treatment of chronic hepatitis C virus (HCV) infections.

The regulator has accepted the company’s marketing authorisation application for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg, for the treatment of chronic HCV genotype 1.

Continue reading this entire article:
http://www.zenopa.com/news/801708681/gilead-sciences-receives-eu-green-light-for-hepatitis-c-drug-assessment

No Comments - be the first!
Share
Share

Previous

Government Impact of Hep C Drug Price Tag

Back to News Homepage

Next

FREE WEBINAR Diagnosing and Treating HE: A Physician's Perspective

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.